Novartis, the Swiss pharmaceutical company, plans to submit 50 new drug applications in China over the next few years, as it projects faster Chinese drug approvals which could see the country overtake Europe to become its second-largest market.
瑞士製藥公司諾華(Novartis)計劃未來幾年在中國提交50份新藥申請。該公司預計，中國的藥品審批程式提速將使中國取代歐洲成爲其第二大市場。
您已閱讀7%（316字），剩餘93%（3954字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。